Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the …

HJL Heerspink, N Jongs, GM Chertow… - The lancet Diabetes & …, 2021 - thelancet.com
Background Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney
disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified …
被引用次数：121 相关文章

Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the …

HJL Heerspink, N Jongs, GM Chertow, AM Langkilde… - 2021 - pubmed.ncbi.nlm.nih.gov
Background Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney
disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified …
[PDF] natap.org

[PDF][PDF] Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis …

HJL Heerspink, N Jongs, GM Chertow, AM Langkilde… - natap.org
Background Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney
disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified …

Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the …

HJL Heerspink, N Jongs, GM Chertow… - The lancet. Diabetes …, 2021 - europepmc.org
Background Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney
disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified …

Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the …

HJL Heerspink, N Jongs, GM Chertow… - Lancet Diabetes …, 2021 - discovery.ucl.ac.uk
BACKGROUND: Dapagliflozin reduced the risk of kidney failure in patients with chronic
kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified …

Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the …

HJL Heerspink, N Jongs, GM Chertow… - Lancet Diabetes & …, 2021 - research.rug.nl
BACKGROUND: Dapagliflozin reduced the risk of kidney failure in patients with chronic
kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified …

Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the …

HJL Heerspink, N Jongs, GM Chertow… - The Lancet Diabetes & …, 2021 - Elsevier
Background Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney
disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified …